Marviette D. Johnson Net Worth

The estimated Net Worth of Marviette D. Johnson is at least $1.62 Milion dollars as of 2 March 2015. Marviette Johnson owns over 1,917 units of Meridian Bioscience stock worth over $1,585,380 and over the last 13 years Marviette sold VIVO stock worth over $38,167.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Marviette Johnson VIVO stock SEC Form 4 insiders trading

Marviette has made over 1 trades of the Meridian Bioscience stock since 2015, according to the Form 4 filled with the SEC. Most recently Marviette sold 1,917 units of VIVO stock worth $38,167 on 2 March 2015.

The largest trade Marviette's ever made was selling 1,917 units of Meridian Bioscience stock on 2 March 2015 worth over $38,167. On average, Marviette trades about 274 units every 0 days since 2011. As of 2 March 2015 Marviette still owns at least 46,670 units of Meridian Bioscience stock.

You can see the complete history of Marviette Johnson stock trades at the bottom of the page.

What's Marviette Johnson's mailing address?

Marviette's mailing address filed with the SEC is 3471 RIVER HILLS DRIVE, , CINCINNATI, OH, 45244.

Insiders trading at Meridian Bioscience

Over the last 22 years, insiders at Meridian Bioscience have traded over $8,089,514 worth of Meridian Bioscience stock and bought 228,244 units worth $3,053,655 . The most active insiders traders include Richard Eberly, John P. Kenny a John A Kraeutler. On average, Meridian Bioscience executives and independent directors trade stock every 41 days with the average trade being worth of $424,761. The most recent stock trade was executed by James M. Anderson on 6 January 2023, trading 8,500 units of VIVO stock currently worth $173,230.

What does Meridian Bioscience do?

Meridian Bioscience Inc. is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.The company is dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, Meridian provides critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, Meridian provides diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. The company builds relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.

Complete history of Marviette Johnson stock trades at Meridian Bioscience

Meridian Bioscience executives and stock owners

Meridian Bioscience executives and other stock owners filed with the SEC include:

• John P. Kenny,
  Pres, CEO & Director
• John Kenny,
  Chief Executive Officer, Director
• Lourdes Weltzien,
  Executive Vice President - Life Science
• Dr. Lourdes G. Weltzien Ph.D.,
  Exec. VP of Life Science Bus. Unit
• Tony Serafini-Lamanna,
  Exec. VP of Diagnostics
• Bryan Baldasare,
  Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Corporate Controller, Treasurer
• David Phillips,
  Independent Chairman of the Board
• James Anderson,
  Independent Director
• Dwight Ellingwood,
  Independent Director
• Felicia Williams,
  Independent Director
• Catherine Sazdanoff,
  Independent Director
• John Rice,
  Independent Director
• John McIlwraith,
  Independent Director
• Anthony Bihl,
  Independent Director
• Melissa A. Lueke,
  Consultant
• Susan D. Rolih,
  Consultant
• Melissa J. McCarey,
  VP of Global HR
• Charles Wood,
  VP of Investor Relations
• Jeff Pinkston,
  Director of Corp. Fin.
• Julie Smith,
  Sr. VP, Controller & Principal Accounting Officer
• Michael C. Shaughnessy,
  EVP, Pres Meridian Global Dx
• Amy Winslow,
  EVP, Pres & CEO of Magellan
• Melissa Lueke,
  Exec VP, CFO
• Marco G. Calzavara,
  Pres & Managing Director, MBE
• Vecheslav A Elagin,
  Sr VP, Research & Development
• Eric S. Rasmussen,
  EVP, Bus. Development/Strategy
• Kenneth Kozak,
  Vice President
• Susan Rolih,
  EVP, Reg & Quality Systems
• Lawrence Baldini,
  VP, Operations
• Robert J Ready,
  Director
• Marviette D. Johnson,
  VP, Human Resources
• Todd W Motto,
  VP, Sales and Marketing
• Grady Barnes,
  VP, Research & Development
• Gregory S Ballish,
  VP, Sales and Marketing
• James Buzard,
  Director
• Richard Eberly,
  Ex. VP, Gen Mgr. Mer. Life Sci
• Gary P Kreider,
  Director
• Vivo Family Limited Partner...,
  10% owner
• William J Motto,
  Chairman, CEO
• Antonio Interno,
  Senior Vice President
• John A Kraeutler,
  Chairman and CEO
• Tony Serafini Lamanna,
  Executive VP-Diagnostics